Patents Represented by Attorney Jane Massey Licata

Find this attorney in the Justia Lawyer Directory

  • Antisense inhibition of integrin beta 3 expression
    Patent number: 6037176
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of integrin beta 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding integrin beta 3. Methods of using these compounds for modulation of integrin beta 3 expression and for treatment of diseases associated with expression of integrin beta 3 are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: March 14, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of SMAD2 expression
    Patent number: 6037142
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Smad2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad2. Methods of using these compounds for modulation of Smad2 expression and for treatment of diseases associated with expression of Smad2 are provided.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: March 14, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of MAP kinase kinase 6 expression
    Patent number: 6033910
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MAP kinase kinase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MAP kinase kinase 6. Methods of using these compounds for modulation of MAP kinase kinase 6 expression and for treatment of diseases associated with expression of MAP kinase kinase 6 are provided.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: March 7, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • 2'-O-alkylated oligoribonucleotides and phosphorothioate analogs complementary to portions of the HIV genome
    Patent number: 6034233
    Abstract: Methods of modulating the activity of the TAR element of HIV are provided. Oligonucleotides having 6 to 50 bases and at least one 2'-O alkyl modification and selected sequences are disclosed.
    Type: Grant
    Filed: November 19, 1991
    Date of Patent: March 7, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: David Ecker, Timothy A. Vickers
  • Polymeric radio frequency resonant tags and method for manufacture
    Patent number: 6031458
    Abstract: The present invention provides polymeric radio frequency resonant tags and methods of manufacturing these tags for use in detection of theft of article for sale.
    Type: Grant
    Filed: August 7, 1998
    Date of Patent: February 29, 2000
    Assignee: IRD/AS
    Inventors: Soren Jacobsen, John Engell, Jorgen Schjerning Lundsgaard, David Morgan Thomas
  • Antisense modulation of RhoC expression
    Patent number: 6030786
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RhoC. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RhoC. Methods of using these compounds for modulation of RhoC expression and for treatment of diseases associated with expression of RhoC are provided.
    Type: Grant
    Filed: September 18, 1998
    Date of Patent: February 29, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Lex M. Cowsert
  • Antisense inhibition of PEPCK-mitochondrial expression
    Patent number: 6030837
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PEPCK-mitochondrial. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PEPCK-mitochondrial. Methods of using these compounds for modulation of PEPCK-mitochondrial expression and for treatment of diseases associated with expression of PEPCK-mitochondrial are provided.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: February 29, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Madeline M. Butler, Lex M. Cowsert
  • Antisense modulation of Ship-2 expression
    Patent number: 6025198
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Ship-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Ship-2. Methods of using these compounds for modulation of Ship-2 expression and for treatment of diseases associated with expression of Ship-2 are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: February 15, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Antisense modulation of PTEN expression
    Patent number: 6020199
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTEN. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTEN. Methods of using these compounds for modulation of PTEN expression and for treatment of diseases associated with expression of PTEN are provided.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: February 1, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of RIP-1 expression
    Patent number: 6020198
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RIP-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RIP-1. Methods of using these compounds for modulation of RIP-1 expression and for treatment of diseases associated with expression of RIP-1 are provided.
    Type: Grant
    Filed: September 25, 1998
    Date of Patent: February 1, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Identification of functional transcription factors synthesized in developing neurons
    Patent number: 6020136
    Abstract: The present invention relates to the identification of biologically active transcription factors which are synthesized and modified in the dendritic compartment of neurons and uses thereof.
    Type: Grant
    Filed: September 16, 1998
    Date of Patent: February 1, 2000
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: James Eberwine
  • Intercutaneous implant device
    Patent number: 6017355
    Abstract: Intercutaneous implant devices useful in intraluminal and extraluminal procedures for externalization of vessels are provided which have a hollow cylinder with an upper and lower end and an interior and exterior surface, said hollow cylinder having a central aperture which is greater in diameter than the exterior expanse of the access site and a length which provides for adequate annular separation of the externalized vessel at the exterior and interior surface of the implant to ensure adequate blood supply to the vessel; a flange extending from the upper end of the hollow cylinder which provides a platform onto which is attached a termination device; and a plane contacting surface extending from the lower end of the hollow cylinder which provides a means for fixation of the implant to the patient.
    Type: Grant
    Filed: June 24, 1998
    Date of Patent: January 25, 2000
    Assignee: Bio TAP A/S
    Inventors: Lasse Leif Hessel, Jorgen Scherning Lundsgaard, Carl Zimmermann-Neilsen, John Engell, Jesper Malling, David Morgan Thomas
  • Antisense modulation of FADD expression
    Patent number: 6015712
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of FADD. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding FADD. Methods of using these compounds for modulation of FADD expression and for treatment of diseases associated with expression of FADD are provided.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: January 18, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Brenda F. Baker, Hong Zhang, Lex M. Cowsert
  • Oligonucleotide modulation of cell adhesion
    Patent number: 6015894
    Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3'-untranslated sequences, and intervening sequences.
    Type: Grant
    Filed: December 2, 1997
    Date of Patent: January 18, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Christopher K. Mirabelli
  • Antisense inhibition of human Smad1 expression
    Patent number: 6013522
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Smad1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad1. Methods of using these compounds for modulation of Smad1 expression and for treatment of diseases associated with expression of Smad1 are provided.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: January 11, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of Smad3 expression
    Patent number: 6013788
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Smad3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad3. Methods of using these compounds for modulation of Smad3 expression and for treatment of diseases associated with expression of Smad3 are provided.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: January 11, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of Smad4 expression
    Patent number: 6013787
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Smad4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad4. Methods of using these compounds for modulation of Smad4 expression and for treatment of diseases associated with expression of Smad4 are provided.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: January 11, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of Jun N-terminal kinase kinase-1 expression
    Patent number: 6010906
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Jun N-terminal Kinase Kinase-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Jun N-terminal Kinase Kinase-1. Methods of using these compounds for modulation of Jun N-terminal Kinase Kinase-1 expression and for treatment of diseases associated with expression of Jun N-terminal Kinase Kinase-1 are provided.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: January 4, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Donna T. Ward, Lex M. Cowsert
  • Antisense inhibition of EGR-1 expression
    Patent number: 6008048
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of EGR-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EGR-1. Methods of using these compounds for modulation of EGR-1 expression and for treatment of diseases associated with expression of EGR-1 are provided.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: December 28, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of phospholipase A2 group IV expression
    Patent number: 6008344
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Phospholipase A2 Group IV. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phospholipase A2 Group IV. Methods of using these compounds for modulation of Phospholipase A2 Group IV expression and for treatment of diseases associated with expression of Phospholipase A2 Group IV are provided.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: December 28, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert